drugset
drugset / Trial / NCT06504446

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446 ↗

Phase 2 Active not recruiting 455 enrolled Nocion Therapeutics IQVIA Pty Ltd · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.

Timeline

Start
2024-09-24
Primary completion
2026-06-15
Completion
2026-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject NOC-110 Unknown 1 mg Inhaled
Subject NOC-110 Unknown 3 mg Inhaled
Subject NOC-110 Unknown 6 mg Inhaled

Indications

No indication recorded.